Laura Conti
YOU?
Author Swipe
View article: Special Issue: “Advances in Immunotherapy for Cancer: From Molecular Basis to Novel Biomarkers and Therapeutic Targets”
Special Issue: “Advances in Immunotherapy for Cancer: From Molecular Basis to Novel Biomarkers and Therapeutic Targets” Open
Over the past decade, immunotherapy has revolutionized the treatment of cancer, emerging as a novel pillar of cancer therapy and markedly improving patient survival across multiple tumor types [...]
View article: In situ sonoporation to enhance the tumour uptake of silicon phthalocyanine and improve PDT effectiveness in a triple negative breast cancer murine model
In situ sonoporation to enhance the tumour uptake of silicon phthalocyanine and improve PDT effectiveness in a triple negative breast cancer murine model Open
The effectiveness of photodynamic therapy (PDT) has been well demonstrated in vitro, but in vivo studies have only shown a delay in tumour growth. Tumour recurrence is often reported in clinical trials and is usually associated with limite…
View article: Novel FAP-Targeted Heptamethine Cyanines for NIRF Imaging Applications
Novel FAP-Targeted Heptamethine Cyanines for NIRF Imaging Applications Open
Fibroblast activation protein (FAP) is a pan-cancer target that is useful for imaging, ideally all epithelial cancers. This work aimed to develop, characterize, and validate two novel FAP-targeted probes for optical imaging, both in vit…
View article: Cancer vaccines: Target antigens, vaccine platforms and preclinical models
Cancer vaccines: Target antigens, vaccine platforms and preclinical models Open
This review provides a comprehensive overview of the evolving landscape of cancer vaccines, highlighting their potential to revolutionize tumor prevention. Building on the success of vaccines against virus-related cancers, such as HPV- and…
View article: 1023 Preclinical development of STING agonist 8803 (IMGS-203) for the treatment of solid tumors
1023 Preclinical development of STING agonist 8803 (IMGS-203) for the treatment of solid tumors Open
View article: Cross-Reactive Immune Response of Bovine Coronavirus Spike Glycoprotein to SARS-CoV-2 Variants of Concern
Cross-Reactive Immune Response of Bovine Coronavirus Spike Glycoprotein to SARS-CoV-2 Variants of Concern Open
The high variability observed in the clinical symptoms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections has been attributed to the presence, in a proportion of infection-naive subjects, of pre-existing cross-react…
View article: PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic cancer
PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic cancer Open
View article: Small-angle X-ray and neutron scattering applied to lipid-based nanoparticles: Recent advancements across different length scales
Small-angle X-ray and neutron scattering applied to lipid-based nanoparticles: Recent advancements across different length scales Open
View article: Supplementary Figure 1 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Figure 1 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Mutation loss in developed CT26 tumors after GAd CD8#5 and CD8#23 vaccine. A) Mice were immunized with mono-epitope GAd CD8#5 or B) CD8#23 vaccines and 14 days later, mice were inoculated s.c. with 2x10^5 CT26 cells. Mutation relative to n…
View article: Data from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Data from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Tumor neoantigens (nAg) represent a promising target for cancer immunotherapy. The identification of nAgs that can generate T-cell responses and have therapeutic activity has been challenging. Here, we sought to unravel the features of nAg…
View article: Supplementary Figure 2 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Figure 2 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Generation of CT26 #5KO and CT26 #23KO cells using CRISPR-Cas9 technology. A) CRISPR/Cas9 strategy used for the generation of CT26 cells lacking of nAg #5. Red arrows represent forward and reverse primers used for PCR. Blue lines 1 and 2 i…
View article: Supplementary Figure 3 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Figure 3 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Primary tumor challenge with NeoAg #5 knocked out CT26 tumor cells. Mice were immunized with CD8#5 mono-epitope vaccine and after 14 days, mice were s.c. inoculated with CT26 cells or CT26 #5KO cells, resulting in 50% and 0% of tumor free …
View article: Supplementary Figure 3 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Figure 3 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Primary tumor challenge with NeoAg #5 knocked out CT26 tumor cells. Mice were immunized with CD8#5 mono-epitope vaccine and after 14 days, mice were s.c. inoculated with CT26 cells or CT26 #5KO cells, resulting in 50% and 0% of tumor free …
View article: Supplementary Figure 6 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Figure 6 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Phenotype characterization of total CD8+ and nAg #23+ CD8+T cells in presence and absence of the “Help”. A) Schematic representation of the experimental set up. B) Representative FACS gating strategy for intratumoral CD8+ T cells. C-D) Phe…
View article: Supplementary Figure 1 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Figure 1 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Mutation loss in developed CT26 tumors after GAd CD8#5 and CD8#23 vaccine. A) Mice were immunized with mono-epitope GAd CD8#5 or B) CD8#23 vaccines and 14 days later, mice were inoculated s.c. with 2x10^5 CT26 cells. Mutation relative to n…
View article: Supplementary Figure 4 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Figure 4 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Characterization of neoAg#23 specific T cell subsets in the presence/ absence of T cell “Help”. A) Schematic representation of the experiment. Mice were s.c. injected with CT26 cells and 5 days later, immunized with GAd vaccines CD4+CD8#23…
View article: Supplementary Figure 2 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Figure 2 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Generation of CT26 #5KO and CT26 #23KO cells using CRISPR-Cas9 technology. A) CRISPR/Cas9 strategy used for the generation of CT26 cells lacking of nAg #5. Red arrows represent forward and reverse primers used for PCR. Blue lines 1 and 2 i…
View article: Supplementary Table 1 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Table 1 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
List of the GAd encoded CT26 neoantigens selected according to: binding predictions for MHC-I (IC50 ≤ 500nM) and MHC-II (binding score ≤ 1); tumor allele frequency (MAF≥ 25%) and RNA expression (mutated RNA reads ≥ 1). The mutated amino ac…
View article: Supplementary Table 1 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Table 1 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
List of the GAd encoded CT26 neoantigens selected according to: binding predictions for MHC-I (IC50 ≤ 500nM) and MHC-II (binding score ≤ 1); tumor allele frequency (MAF≥ 25%) and RNA expression (mutated RNA reads ≥ 1). The mutated amino ac…
View article: Supplementary Figure 6 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Figure 6 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Phenotype characterization of total CD8+ and nAg #23+ CD8+T cells in presence and absence of the “Help”. A) Schematic representation of the experimental set up. B) Representative FACS gating strategy for intratumoral CD8+ T cells. C-D) Phe…
View article: Data from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Data from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Tumor neoantigens (nAg) represent a promising target for cancer immunotherapy. The identification of nAgs that can generate T-cell responses and have therapeutic activity has been challenging. Here, we sought to unravel the features of nAg…
View article: Supplementary Figure 5 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Figure 5 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Representative numbers of total and #23+ CD8+ T cells in tumor and spleen of Help versus non Help vaccine. A) Experimental scheme, FACS gating strategy with representative FACS plots of intratumoral #23+ CD8+ T cells in Help group and untr…
View article: Supplementary Figure 4 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Figure 4 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Characterization of neoAg#23 specific T cell subsets in the presence/ absence of T cell “Help”. A) Schematic representation of the experiment. Mice were s.c. injected with CT26 cells and 5 days later, immunized with GAd vaccines CD4+CD8#23…
View article: Supplementary Figure 5 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Figure 5 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Representative numbers of total and #23+ CD8+ T cells in tumor and spleen of Help versus non Help vaccine. A) Experimental scheme, FACS gating strategy with representative FACS plots of intratumoral #23+ CD8+ T cells in Help group and untr…
View article: Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Tumor neoantigens (nAg) represent a promising target for cancer immunotherapy. The identification of nAgs that can generate T-cell responses and have therapeutic activity has been challenging. Here, we sought to unravel the features of nAg…
View article: Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjects
Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjects Open
Background Few data are available about the durability of the response, the induction of neutralizing antibodies, and the cellular response upon the third dose of the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccin…
View article: The Role of the Toll-like Receptor 2 and the cGAS-STING Pathways in Breast Cancer: Friends or Foes?
The Role of the Toll-like Receptor 2 and the cGAS-STING Pathways in Breast Cancer: Friends or Foes? Open
Breast cancer stands as a primary malignancy among women, ranking second in global cancer-related deaths. Despite treatment advancements, many patients progress to metastatic stages, posing a significant therapeutic challenge. Current ther…
View article: FK506 bypasses the effect of erythroferrone in cancer cachexia skeletal muscle atrophy
FK506 bypasses the effect of erythroferrone in cancer cachexia skeletal muscle atrophy Open
View article: A Magnetic Resonance Imaging‐Chemical Exchange Saturation Transfer (MRI‐CEST) Method for the Detection of Water Cycling across Cellular Membranes
A Magnetic Resonance Imaging‐Chemical Exchange Saturation Transfer (MRI‐CEST) Method for the Detection of Water Cycling across Cellular Membranes Open
Water cycling across the membrane transporters is considered a hallmark of cellular metabolism and it could be of high diagnostic relevance in the characterization of tumors and other diseases. The method relies on the response of intracel…
View article: 829 A potent STING agonist in combination with a novel anti-PD-L1/PD-L2 antibody leads to significant tumor responses in checkpoint-refractory cancers
829 A potent STING agonist in combination with a novel anti-PD-L1/PD-L2 antibody leads to significant tumor responses in checkpoint-refractory cancers Open
Background Activation of stimulator of interferon genes (STING) has shown great potential to enhance antitumor immunity. Several synthetic STING agonists have been tested preclinically and in the clinic. However, these molecules are suscep…